XW043QB
Introduction of Iloprost into Central Vein, Percutaneous Approach, New Technology Group 11
Introduce Iloprost in Central Vein, Perc, New Tech 11
Axis Breakdown
Every ICD-10-PCS code is exactly seven characters, one per axis. Each character's meaning is defined by its position in the code.
| Position | Value | Meaning |
|---|---|---|
| 1 | SectionX | New Technology |
| 2 | Body SystemW | Anatomical Regions |
| 3 | Root Operation0 | Introduction Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products |
| 4 | Body Part4 | Central Vein |
| 5 | Approach3 | Percutaneous |
| 6 | Device / Substance / TechnologyQ | Iloprost |
| 7 | New Technology GroupB | New Technology Group 11 |
Related Codes
Same operation — other Body Part
Same table and root operation, differing only in the body part character.
XW033QB — Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11
Same operation — other Device / Substance / Technology
Same table and root operation, differing only in the device / substance / technology character.
XW0430B — Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11, XW0431B — Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11, XW043FB — Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11, XW043PB — Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11, XW043RB — Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11, XW043WB — Introduction of Fosfomycin Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11
Same operation — other Qualifier
Same table and root operation, differing only in the qualifier character.
XW043Q5 — Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5, XW043Q9 — Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9
Contextual Map
Every relationship of XW043QB in one view: hierarchy, official tabular instructions in both directions, clinical classification, risk adjustment, MS-DRG participation, index terms and change history — each edge carrying the CMS source it derives from.
PCS table
- XW0[PCS table]
- [object Object] — Section: [object Object] [Section]: “[object Object]”
- [object Object] — Body System: [object Object] [Body System]: “[object Object]”
- [object Object] — Operation: [object Object] [Operation]: “[object Object]”
Nearest codes
- XW033QB — Introduction of Iloprost into Peripheral Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
- XW0430B — Introduction of Alpha1-proteinase Inhibitor into Central Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
- XW0431B — Introduction of Anitocabtagene Autoleucel Immunotherapy into Central Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
- XW043FB — Introduction of Valoctocogene Roxaparvovec-rvox into Central Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
- XW043PB — Introduction of Aztreonam-avibactam Anti-infective into Central Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
- XW043Q5 — Introduction of Tagraxofusp-erzs Antineoplastic into Central Vein, Percutaneous Approach, New Technology Group 5 [One axis away]
- XW043Q9 — Introduction of Posoleucel into Central Vein, Percutaneous Approach, New Technology Group 9 [One axis away]
- XW043RB — Introduction of Letetresgene Autoleucel into Central Vein, Percutaneous Approach, New Technology Group 11 [One axis away]
Change history
No changes recorded for this code — unchanged since the FY2026 (April) baseline of the change ledger.